
|Articles|August 13, 2008
FDA warns of adverse reactions to naltrexone
The FDA said patients should monitor the injection site.
Advertisement
The Food and Drug Administration is
The FDA said patients should monitor the injection site and contact a physician if they develop pain, swelling, tenderness, induration, bruising, pruritus, or redness that does not improve or worsens within two weeks.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
2
ACIP's Vacancy Leaves Pharmacists Navigating COVID-19 Confusion
3
Tirzepatide Receives Expanded Approval for MACE in Patients With T2D
4
The Drug Price Paradox: PBMs, Pharmacies, and the Path to Affordability
5































